{"id":11360,"date":"2025-08-06T08:27:45","date_gmt":"2025-08-06T05:27:45","guid":{"rendered":"https:\/\/grindeks.com\/?p=11360"},"modified":"2025-08-06T08:27:51","modified_gmt":"2025-08-06T05:27:51","slug":"grindeks-pedeja-transformacijas-gada-pirmaja-puse-strauja-izaugsme-un-nostiprinatas-pozicijas-eiropas-tirgos","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-pedeja-transformacijas-gada-pirmaja-puse-strauja-izaugsme-un-nostiprinatas-pozicijas-eiropas-tirgos\/","title":{"rendered":"Grindeks p\u0113d\u0113j\u0101 transform\u0101cijas gada pirmaj\u0101 pus\u0113 strauja izaugsme un nostiprin\u0101tas poz\u012bcijas Eiropas tirgos"},"content":{"rendered":"\n

AS \u201cGrindeks\u201d finan\u0161u dati liecina, ka 2025. gada pirmaj\u0101 pusgad\u0101 \u2013 p\u0113d\u0113j\u0101 transform\u0101cijas gad\u0101 \u2013 koncerns ir sasniedzis b\u016btiskus pe\u013c\u0146as r\u0101d\u012bt\u0101jus. Laika period\u0101 no janv\u0101ra l\u012bdz maijam \u201cGrindeks\u201d pe\u013c\u0146a sasniedza 13 miljonus eiro. \u0160ie rezult\u0101ti apliecina, ka strat\u0113\u0123isk\u0101 virz\u012bba uz stabilu un prognoz\u0113jamu eksporta tirgu att\u012bst\u012bbu Eirop\u0101, Zieme\u013camerik\u0101, \u0100zij\u0101 un Austr\u0101lij\u0101 ir bijusi pamatota un sekm\u012bga.<\/p>\n\n\n\n

\n

AS \u201cGrindeks\u201d padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans:<\/strong>
\u201c2025. gads ir z\u012bm\u012bgs posms \u201cGrindeks\u201d att\u012bst\u012bb\u0101 \u2013 m\u0113s ne tikai nosl\u0113dzam v\u0113rien\u012bgu p\u0101rmai\u0146u procesu, bet ar\u012b redzam konkr\u0113tus rezult\u0101tus no gadiem ilgi veiktajiem ieguld\u012bjumiem. Ra\u017eo\u0161ana ir m\u016bsu pamats, un m\u0113s to veidojam, balstoties uz ilgtermi\u0146a redz\u0113jumu. \u201cGrindeks\u201d m\u0113r\u0137is ir nep\u0101rprotams \u2013 b\u016bt starptautiskam z\u012bmolam ar stabilu pamatu Latvij\u0101, kas nodro\u0161ina pacientiem vis\u0101 pasaul\u0113 augst\u0101k\u0101s kvalit\u0101tes medikamentus. Turpin\u0101sim papla\u0161in\u0101ties, invest\u0113t un att\u012bst\u012bt farm\u0101cijas nozari Latvij\u0101 k\u0101 eksporta nozari ar augstu pievienoto v\u0113rt\u012bbu.\u201d<\/p>\n<\/blockquote>\n\n\n\n

Rezult\u0101tu pamat\u0101 ir stabils piepras\u012bjuma pieaugums p\u0113c sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko, ko nodro\u0161ina \u201cGrindeks\u201d, un slimn\u012bcu segmenta medikamentiem, ko nodro\u0161ina meitasuz\u0146\u0113mums \u201cKalceks\u201d. Visos meitasuz\u0146\u0113mumos ir uzs\u0101kta akt\u012bva tirdzniec\u012bba \u2013 tie pied\u0101v\u0101 \u201cGrindeks\u201d un \u201cKalceks\u201d z\u012bmola produktus, piedal\u0101s iepirkumos un nodro\u0161ina tie\u0161\u0101s pieg\u0101des aptiek\u0101m Eiropas valst\u012bs. No re\u0123ion\u0101l\u0101 uz\u0146\u0113muma esam k\u013cuvu\u0161i par pasaules m\u0113roga koncernu, kura produktu kl\u0101sts \u0161obr\u012bd ir pieejams vis\u0101s ES valst\u012bs. Vien\u0101 valst\u012b liel\u0101kais pieejamais produktu skaits ir 56, bet maz\u0101kais \u2013 16. M\u016bsu m\u0113r\u0137is n\u0101kamajiem pieciem gadiem \u2013 att\u012bst\u012bt portfeli t\u0101, lai katr\u0101 valst\u012b b\u016btu pieejami vismaz 100 produkti.<\/p>\n\n\n\n

Lai nodro\u0161in\u0101tu pieejam\u012bbu un efekt\u012bvu tirdzniec\u012bbas \u0137\u0113di, \u201cGrindeks\u201d grupa ir atv\u0113rusi meitasuz\u0146\u0113mumus Eirop\u0101, Zieme\u013camerik\u0101, \u0100zij\u0101 un Austr\u0101lij\u0101. Ra\u017eo\u0161anas kapacit\u0101ti koncerns nodro\u0161ina ar\u012b \u0101rpus Latvijas \u2013 ar ra\u017eotn\u0113m Igaunij\u0101 (\u201cTallinas farmaceitisk\u0101 r\u016bpn\u012bca\u201d) un Slov\u0101kij\u0101 (\u201cHBM Pharma\u201d), kas b\u016btiski stiprina grupas glob\u0101lo darb\u012bbu un sp\u0113ju piel\u0101goties piepras\u012bjumam da\u017e\u0101dos tirgos.<\/p>\n\n\n\n

Eksporta tirgi un meitasuz\u0146\u0113mumi<\/strong><\/p>\n\n\n\n

Lai veicin\u0101tu stabilu un ilgtermi\u0146a izaugsmi, \u201cGrindeks\u201d grupa akt\u012bvi papla\u0161ina savu kl\u0101tb\u016btni jaunos eksporta tirgos ar augstu att\u012bst\u012bbas potenci\u0101lu. No 2022. gada uzs\u0101kta m\u0113r\u0137tiec\u012bga strat\u0113\u0123ija, kuras ietvaros izveidoti meitasuz\u0146\u0113mumi Eirop\u0101 un citviet pasaul\u0113.<\/p>\n\n\n\n

\u0160obr\u012bd \u201cGrindeks\u201d meitasuz\u0146\u0113mumi darbojas Eirop\u0101, Zieme\u013camerik\u0101, \u0100zij\u0101 un Austr\u0101lij\u0101. \u0160\u0101da \u0123eogr\u0101fisk\u0101 diversifik\u0101cija samazina riskus un nodro\u0161ina, ka m\u016bsu produkti ir pieejami pacientiem vis\u0101 pasaul\u0113 \u2013 vair\u0101k nek\u0101 100 valst\u012bs. Tas apliecina m\u016bsu ap\u0146\u0113m\u012bbu k\u013c\u016bt par glob\u0101lu farm\u0101cijas uz\u0146\u0113mumu ar ilgtsp\u0113j\u012bgu un konkur\u0113tsp\u0113j\u012bgu pied\u0101v\u0101jumu.<\/p>\n\n\n\n

Produktu att\u012bst\u012bba un inov\u0101cijas<\/strong><\/p>\n\n\n\n

Lai nodro\u0161in\u0101tu pieaugo\u0161o piepras\u012bjumu p\u0113c kvalitat\u012bv\u0101m z\u0101l\u0113m, \u201cGrindeks\u201d intens\u012bvi invest\u0113 p\u0113tniec\u012bb\u0101 un att\u012bst\u012bb\u0101. \u0160obr\u012bd da\u017e\u0101dos izstr\u0101des posmos ir 122 jauni farmaceitiskie produkti, kas aptver noz\u012bm\u012bgas terapeitisk\u0101s jomas \u2013 sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, diab\u0113ta, dermatolo\u0123ijas un onkolo\u0123ijas slim\u012bbu \u0101rst\u0113\u0161anu. P\u0113d\u0113jo tr\u012bs gadu laik\u0101 Eiropas savien\u012bb\u0101 decentraliz\u0113tas re\u0123istr\u0101cijas proced\u016bras ce\u013c\u0101 re\u0123istr\u0113ti 23 jauni produkti.<\/p>\n\n\n\n

Svar\u012bga loma koncerna darb\u012bb\u0101 ir akt\u012bvo farmaceitisko vielu (AFV) ra\u017eo\u0161anai \u2013 tas ir b\u016btisks konkurences priek\u0161roc\u012bbas faktors un palielina uz\u0146\u0113muma neatkar\u012bbu no izejvielu pieg\u0101d\u0101t\u0101jiem. \u0160obr\u012bd tiek ra\u017eotas 30 AFV, bet izstr\u0101d\u0113 ir v\u0113l 36 jaunas vielas, kuras n\u0101kotn\u0113 nodro\u0161in\u0101s v\u0113l liel\u0101ku integr\u0101ciju ra\u017eo\u0161anas \u0137\u0113d\u0113.<\/p>\n","protected":false},"excerpt":{"rendered":"

AS \u201cGrindeks\u201d finan\u0161u dati liecina, ka 2025. gada pirmaj\u0101 pusgad\u0101 \u2013 p\u0113d\u0113j\u0101 transform\u0101cijas gad\u0101 \u2013 koncerns ir sasniedzis b\u016btiskus pe\u013c\u0146as r\u0101d\u012bt\u0101jus. Laika period\u0101 no janv\u0101ra…<\/p>\n","protected":false},"author":6,"featured_media":11361,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-11360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/11360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=11360"}],"version-history":[{"count":1,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/11360\/revisions"}],"predecessor-version":[{"id":11365,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/11360\/revisions\/11365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/11361"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=11360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=11360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=11360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}